Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 248

1.

Side effects associated with ultrarapid cytochrome P450 2D6 genotype among women with early stage breast cancer treated with tamoxifen.

Rolla R, Vidali M, Meola S, Pollarolo P, Fanello MR, Nicolotti C, Saggia C, Forti L, Agostino FD, Rossi V, Borra G, Stratica F, Alabiso O, Bellomo G.

Clin Lab. 2012;58(11-12):1211-8.

PMID:
23289191
2.

Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.

Karle J, Bolbrinker J, Vogl S, Kreutz R, Denkert C, Eucker J, Wischnewsky M, Possinger K, Regierer AC.

Breast Cancer Res Treat. 2013 Jun;139(2):553-60. doi: 10.1007/s10549-013-2565-3. Epub 2013 May 18.

PMID:
23686417
3.

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G; Breast International Group (BIG) 1-98 Collaborative Group.

J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. doi: 10.1093/jnci/djs125. Epub 2012 Mar 6.

4.

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H.

JAMA. 2009 Oct 7;302(13):1429-36. doi: 10.1001/jama.2009.1420.

5.

Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment.

Park HS, Choi JY, Lee MJ, Park S, Yeo CW, Lee SS, Shin JG, Park BW.

J Korean Med Sci. 2011 Aug;26(8):1007-13. doi: 10.3346/jkms.2011.26.8.1007. Epub 2011 Jul 27.

6.

Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.

Park IH, Ro J, Park S, Lim HS, Lee KS, Kang HS, Jung SY, Lee S.

Breast Cancer Res Treat. 2012 Jan;131(2):455-61. doi: 10.1007/s10549-011-1425-2. Epub 2011 Mar 25.

PMID:
21437611
7.

Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.

Damodaran SE, Pradhan SC, Umamaheswaran G, Kadambari D, Reddy KS, Adithan C.

Cancer Chemother Pharmacol. 2012 Jul;70(1):75-81. doi: 10.1007/s00280-012-1891-1. Epub 2012 May 24.

PMID:
22623212
8.

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M; ATAC trialists.

J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6. Erratum in: J Natl Cancer Inst. 2012 Nov 21;104(22):1772.

9.

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.

Gaston C, Kolesar J.

Clin Adv Hematol Oncol. 2008 Nov;6(11):825-33.

PMID:
19194367
10.

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.

Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA.

Clin Pharmacol Ther. 2006 Jul;80(1):61-74.

11.

Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy.

Lyon E, Gastier Foster J, Palomaki GE, Pratt VM, Reynolds K, Sábato MF, Scott SA, Vitazka P; working group of the Molecular Genetics Subcommittee on behalf of the American College of Medical Genetics and Genomics ACMG) Laboratory Quality Assurance Committee.

Genet Med. 2012 Dec;14(12):990-1000. doi: 10.1038/gim.2012.108. Epub 2012 Sep 6. Review.

PMID:
22955113
12.

No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.

Markkula A, Hjertberg M, Rose C, Ingvar C, Jernström H.

Acta Oncol. 2014 Feb;53(2):195-200. doi: 10.3109/0284186X.2013.840739. Epub 2013 Oct 14.

PMID:
24125101
13.

CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients.

Yazdi MF, Rafieian S, Gholi-Nataj M, Sheikhha MH, Nazari T, Neamatzadeh H.

Asian Pac J Cancer Prev. 2015;16(15):6783-7.

14.

CYP2D6 polymorphisms and the impact on tamoxifen therapy.

Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD.

J Pharm Sci. 2007 Sep;96(9):2224-31. Review.

PMID:
17518364
15.

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN.

Breast Cancer Res Treat. 2007 Jan;101(1):113-21. Epub 2006 Nov 18.

PMID:
17115111
16.

Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer.

Zafra-Ceres M, de Haro T, Farez-Vidal E, Blancas I, Bandres F, de Dueñas EM, Ochoa-Aranda E, Gomez-Capilla JA, Gomez-Llorente C.

Int J Med Sci. 2013 May 27;10(7):932-7. doi: 10.7150/ijms.5708. Print 2013.

17.

Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.

Singh MS, Francis PA, Michael M.

Breast. 2011 Apr;20(2):111-8. doi: 10.1016/j.breast.2010.11.003. Epub 2010 Dec 24. Review.

PMID:
21185724
18.

Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis.

Seruga B, Amir E.

Breast Cancer Res Treat. 2010 Aug;122(3):609-17. doi: 10.1007/s10549-010-0902-3. Epub 2010 May 8.

PMID:
20454926
19.

Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.

Kiyotani K, Mushiroda T, Sasa M, Bando Y, Sumitomo I, Hosono N, Kubo M, Nakamura Y, Zembutsu H.

Cancer Sci. 2008 May;99(5):995-9. doi: 10.1111/j.1349-7006.2008.00780.x. Epub 2008 Feb 24.

20.

Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.

Stingl JC, Parmar S, Huber-Wechselberger A, Kainz A, Renner W, Seeringer A, Brockmöller J, Langsenlehner U, Krippl P, Haschke-Becher E.

Curr Med Res Opin. 2010 Nov;26(11):2535-42. doi: 10.1185/03007995.2010.518304. Epub 2010 Sep 17.

PMID:
20849243

Supplemental Content

Support Center